Furthermore, the number of CFTR variants per person was actually greater in both control groups (family members not infected with NTM and in the 1000G Project cohort) than in NTM-LD subjects [81]—in contrast to the other three non-CFTR gene categories in which the number of variants was least in the control 1000G Project cohort—it favors the possibility that the risk for NTM-LD in CF patients is perhaps due to the presence of bronchiectasis and not to the CFTR mutation per se. This evidence concerns the gene CFTR and bronchiectasis.